Thoennissen Nils H, Schneider Michael, Allroggen Achim, Ritter Martin, Dittrich Ralf, Schmid Christof, Scheld Hans H, Ringelstein E Bernd, Nabavi Darius G
Department of Neurology, University of Münster, Münster, Germany.
J Thorac Cardiovasc Surg. 2005 Oct;130(4):1159-66. doi: 10.1016/j.jtcvs.2005.02.068.
Microembolic signals detected by transcranial Doppler ultrasonography have been demonstrated to be clinically relevant in patients supported with pulsatile left ventricular assist devices. We prospectively investigated the quantity of microembolic signals in patients supported with the continuous-flow DeBakey left ventricular assist device (MicroMed DeBakey VAD; MicroMed Technology, Inc, Houston, Tex) including the refined Carmeda BioActive Surface system (Carmeda AB, Stockholm, Sweden).
Twenty-three patients (20 male) aged 14 to 62 years supported with DeBakey left ventricular assist devices (n = 6 with Carmeda) were enrolled in this study. Microembolic signal monitorings were performed twice weekly by insonating the middle cerebral artery for 20 minutes without and 20 minutes with oronasal application of oxygen (6 L/min). Evidence of clinically manifest thromboembolic events was based on regular questionnaires, clinical examinations, and results of diagnostic procedures.
Despite a low incidence of thromboembolic complications (0.24 per 100 left ventricular assist device days), 20 patients (87%) showed circulating microemboli. Overall, microembolic signals were found in 175 of 499 transcranial Doppler ultrasonographic examinations (35.1%), with mean counts of 81.2 +/- 443 (range 0-5042 signals/h). Both microembolic signal prevalence (25% vs 34%, P = .01) and absolute signal counts (46.5 vs 104, P < .01) significantly declined with oxygen delivery. There was no significant correlation between the individual microembolic signal activity and the incidence of clinical thromboembolism or the intensity of antihemostatic treatment. Patients supported with the Carmeda device did not show reduced rates of clinical thromboembolization or cerebral microemboli.
In patients with DeBakey left ventricular assist devices, a high load of clinically silent microemboli can be detected within the cerebral arteries despite a low incidence of embolic complications. It needs to be investigated whether such continuous, presumably gaseous microembolization causes cognitive or neuropsychologic deficits.
经颅多普勒超声检测到的微栓塞信号已被证明在使用搏动性左心室辅助装置的患者中具有临床相关性。我们前瞻性地研究了使用连续流德巴基左心室辅助装置(MicroMed德巴基VAD;MicroMed Technology公司,休斯顿,德克萨斯州)包括改良的卡美达生物活性表面系统(卡美达AB公司,斯德哥尔摩,瑞典)的患者中的微栓塞信号数量。
本研究纳入了23例年龄在14至62岁之间、使用德巴基左心室辅助装置(6例使用卡美达)的患者(20例男性)。每周两次通过对大脑中动脉进行20分钟的超声检查来进行微栓塞信号监测,一次在未口鼻吸氧(6L/分钟)时,一次在口鼻吸氧时。临床明显血栓栓塞事件的证据基于定期问卷调查、临床检查和诊断程序结果。
尽管血栓栓塞并发症的发生率较低(每100个左心室辅助装置日0.24次),但20例患者(87%)显示有循环微栓子。总体而言,在499次经颅多普勒超声检查中有175次发现微栓塞信号(35.1%),平均计数为81.2±443(范围0 - 5042信号/小时)。随着氧气输送,微栓塞信号的患病率(25%对34%,P = 0.01)和绝对信号计数(46.5对104,P < 0.01)均显著下降。个体微栓塞信号活性与临床血栓栓塞发生率或抗止血治疗强度之间无显著相关性。使用卡美达装置的患者临床血栓栓塞或脑微栓子发生率并未降低。
在使用德巴基左心室辅助装置的患者中,尽管栓塞并发症发生率较低,但在脑动脉内可检测到大量临床上无症状的微栓子。需要研究这种持续的、可能是气态的微栓塞是否会导致认知或神经心理缺陷。